Premium
In vivo imaging of the cannabinoid CB 1 receptor with positron emission tomography
Author(s) -
Hirvonen J
Publication year - 2015
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt.116
Subject(s) - positron emission tomography , brain positron emission tomography , preclinical imaging , in vivo , nuclear medicine , positron emission , positron , pet imaging , positron emission tomography computed tomography , physics , nuclear magnetic resonance , medicine , medical physics , chemistry , nuclear physics , biology , genetics , electron
Positron emission tomography (PET) can visualize and quantify receptors and other targets in the living human brain, and recent progress in radioligand development has enabled measurement of cannabinoid type‐1 (CB 1 ) receptors. Cannabinoid CB 1 receptors have been implicated in multiple human diseases, such as obesity, mood disorders, and addiction. First in vivo human studies have shown distinctive spatial and temporal alterations in cannabinoid CB 1 receptor binding in addictive disorders.